Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
Life challenges make this population very difficult to treat, but interventions that take their issues into account may ...
The South African National Aids Council is meant to play a co-ordinating role in the country’s response to HIV, bringing ...
The Ghana AIDS Commission (GAC) says the lack of funding can impact negatively efforts to end AIDS as a public health threat ...
The new rule, built on previous guidance for the Affordable Care Act, also applies to increased choice in contraception.
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.
Health authorities in Rio de Janeiro are reviewing samples from 288 donors after discovering that two HIV-positive people ...
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback